Acer Therapeutics Inc

-0.03 (-1.49%)
Earnings Announcements

Acer Therapeutics Reports Q3 Loss Per Share $0.23

Published: 11/19/2021 22:37 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update.
Q3 Loss per Share $0.23.
Believes Cash & Cash Equivalents Are Sufficient to Fund Currently Anticipated Operating & Capital Requirements Into Mid-2022.
Cash and Cash Equivalents Will Be Sufficient Into Mid-2022 Excluding Support for Planned Acer-801 and Edsivo Clinical Trials.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.